反应详情

The title compound was prepared in the same manner as described in example 74 using 6-chloro-N-[(4,6-dimethyl-2-oxo-1,2-dihydro-3-pyridinyl)methyl]-1-(1-methylethyl)-1H-pyrazolo[3,4-b]pyridine-4-carboxamide (70 mg, 0.187 mmol), 5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1,3-dihydro-2H-indol-2-one (63.1 mg, 0.243 mmol), DMSO (1.5 mL), sodium carbonate (0.281 mL, 0.562 mmol), and bis(triphenylphosphine)palladium(II) chloride (10.51 mg, 0.015 mmol). The final product was collected as 30 mg (34%). LCMS E-S (M+H)=471.3 1H NMR (400 MHz, DMSO-d6) δ ppm 1.54 (d, J=6.4 Hz, 6H), 2.13 (s, 3H), 2.22 (s, 3H), 3.40 (br. s., 2H), 4.41 (d, J=4.6 Hz, 2H), 5.25-5.41 (m, 1H), 5.91 (s, 1H), 6.97 (d, J=8.1 Hz, 1H), 8.08-8.21 (m, 3H), 8.34 (s, 1H), 8.96 (br. s., 1H), 10.64 (s, 1H), 11.58 (br. s., 1H).

1. customThe final product was collected as 30 mg (34%)